Oluwafemi Ojo Agosile

Oluwafemi Ojo Agosile

Auto-generated profile, based on publicly available information

Oluwafemi Ojo Agosile

Adekunle Ajasin University

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
EOEmmanuel Sunday Omirin
Emmanuel Sunday Omirin
OOOlaposi Idowu Omotuyi
Olaposi Idowu Omotuyi
OAOluwaseun Grace Afokhume
Oluwaseun Grace Afokhume
EOEhisdiame Favour Okoh
Ehisdiame Favour Okoh
SBSamuel Oluwaseun Boboye
Samuel Oluwaseun Boboye
OAOluwafemi Ojo Agosile
Oluwafemi Ojo Agosile
The target of most cancer chemotherapeutic agents is to drive cancer cells toward death. A fine balance between anti-apoptotic and pro-apoptotic proteins is needed to maintain cellular homeostasis. Any shift favoring the pro-apoptotic ones is needed to drive cellular death in cancer chemotherapy. However, anti-apoptotic proteins such as Bcl-2 and Bcl-xL bind with pro-apoptotic proteins to hinder apoptosis mechanisms. Overexpression of these anti-apoptotic proteins lead to several cancers by preventing apoptosis. In this study, molecular docking, ADMET predictions, and molecular dynamics simulations were performed for the identification of potent inhibitors of anti-apoptotic Bcl-2 with compounds of Morus alba. Our study discovered that Quercetin-3-(6-Malonylglucoside) and Epigallocatechin gallate recorded excellent binding affinity with Bcl-2. Therefore, we conclude that compounds of Morus alba should be subjected to further experimental studies ( in vitro and in vivo) in order to confirm the findings that they could be used as better options in cancer chemotherapy.

1 July 2026 in Next Research
Verified
Journal Article
Closed access
AOAfolabi Owoloye
Afolabi Owoloye
FLFunmilayo C. Ligali
Funmilayo C. Ligali
OEOjochenemi A. Enejoh
Ojochenemi A. Enejoh
OAOluwafemi Agosile
Oluwafemi Agosile
AMAdesola Z. Musa
Adesola Z. Musa
KOKolapo M. Oyebola
Kolapo M. Oyebola

22 June 2023 in Research Square
Verified
Preprint
Open access
PDF file
OAOluwafemi Ojo Agosile
Oluwafemi Ojo Agosile
PNPrisca Chinonso Njoku
Prisca Chinonso Njoku
UOUgochukwu Oduwe
Ugochukwu Oduwe
AAAyokanmi Joseph Aremu
Ayokanmi Joseph Aremu
SFSunday Joseph Fajobi
Sunday Joseph Fajobi
EOEmmanuel Sunday Omirin
Emmanuel Sunday Omirin
More than 19 percent of all human cancer cases globally express mutant RAS proteins, which are the most frequently altered oncogenic proteins. Targeting cancer cells becomes difficult because these oncogenic proteins and cancer cells that are driven by Ras mutation show very aggressive traits. KRAS is the most expressed among the three isoforms of Ras mutation, which usually occur at position 12. KRAS G12C and KRAS G12D are common types of KRAS that have been proven difficult to target for many years. In recent times, many studies started to show that a lot of food spices possess strong anticancer properties that can target many cancer cells. Therefore, computational methods to access the anticancer properties of some selected compounds that are present in common food spices against KRAS G12C and KRAS G12D in their inactive GDP-bound state. These compounds were molecularly docked with standard drugs after their ADMET screening revealed their druglikeness. Chlorogenic acid and Rosmarinic acid displayed better binding affinity to the targets than all other drugs studied in this research. Molecular dynamics simulation was used to verify this compound's stability. Therefore, after extensive experimental effort, it is most likely that Rosmarinic acid would be effective as a KRAS G12C medicine.